SCHEMBL22925090

SCHEMBL22925090

O=C(Cc1cc(F)cc(F)c1)c1ccc(OC2CCCCO2)cc1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.43
ALDH1A1 P00352 3/20 0.43
NPSR1 Q6W5P4 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
LMNA P02545 3/20 0.43
HTT P42858 1/20 0.43
CTSD P07339 1/20 0.41
BACE1 P56817 1/20 0.41
NPC1 O15118 5/20 0.40
RAB9A P51151 5/20 0.40
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
CYP3A4 P08684 1/20 0.40
ATM Q13315 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ESR1 P03372 1/20 0.38
SHBG P04278 1/20 0.38
ESR2 Q92731 1/20 0.38
MAPT P10636 2/20 0.37
DHFR P00374 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29574775 1.00 HPGD (0.43) HPGDALDH1A1NPSR1SMN1; SMN2LMNA
SCHEMBL16341669 0.92 LMNA (0.54) HPGDALDH1A1NPSR1SMN1; SMN2LMNA
SCHEMBL17838414 0.92 CTSD (0.41) HPGDALDH1A1NPSR1SMN1; SMN2LMNA
SCHEMBL29574409 0.92 CTSD (0.41) HPGDALDH1A1NPSR1SMN1; SMN2LMNA
SCHEMBL18179373 0.90 HPGD (0.42) HPGDALDH1A1NPSR1SMN1; SMN2LMNA
SCHEMBL1940843 0.89 HPGD (0.49) HPGDALDH1A1NPSR1SMN1; SMN2LMNA
SCHEMBL12930769 0.88 ESR1 (0.52) HPGDALDH1A1NPSR1SMN1; SMN2LMNA
SCHEMBL18170299 0.87 NPC1 (0.44) HPGDALDH1A1NPSR1SMN1; SMN2LMNA
SCHEMBL16323046 0.83 LMNA (0.44) HPGDALDH1A1SMN1; SMN2LMNAHTT
SCHEMBL15096954 0.83 HPGD (0.46) HPGDALDH1A1NPSR1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11014915-B2 Selective estrogen receptor degrader SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2021-05-25 US disclosed
US-20210024504-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADER SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2021-01-28 US disclosed
WO-2021014386-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADER SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2021-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210024504-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADER ESR1, GPER1, ESR2 HPGD 1358/4885ALDH1A1 1106/4885NPSR1 1232/4885
US-11014915-B2 Selective estrogen receptor degrader ESR1, GPER1, ESR2 HPGD 1358/4885ALDH1A1 1106/4885NPSR1 1232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.